Eldecalcitol reduces osteoporotic fractures by unique mechanisms

Journal of Steroid Biochemistry and Molecular Biology

Volumn 148, Issue , 2015, Pages 232-238

  Kondo, Satoshi ^a   Takano, Toshiyuki ^a   Ono, Yoshiyuki ^a   Saito, Hitoshi ^a   Matsumoto, Toshio ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hypercalcemia; Hypercalciuria; Renal function; Vitamin D 24 hydroxylase (CYP24A1); Vitamin D receptor (VDR); Vitamin D binding protein (DBP)

Indexed keywords

ALFACALCIDOL; CALCIUM; ELDECALCITOL; CALCITRIOL; CALCITRIOL RECEPTOR; COLECALCIFEROL 24 HYDROXYLASE; CYP24A1 PROTEIN, HUMAN; MESSENGER RNA; VITAMIN; VITAMIN D; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYDRATION; HYPERCALCEMIA; HYPERCALCIURIA; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIMARY OSTEOPOROSIS; UROLITHIASIS; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BONE DENSITY; CHEMISTRY; DRUG EFFECTS; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CONFORMATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X RAY CRYSTALLOGRAPHY;

AGED; BONE DENSITY; CALCITRIOL; CALCIUM; CLINICAL TRIALS, PHASE III AS TOPIC; CRYSTALLOGRAPHY, X-RAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PROTEIN CONFORMATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VITAMIN D; VITAMIN D-BINDING PROTEIN; VITAMIN D3 24-HYDROXYLASE; VITAMINS;

EID: 84925462868     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2015.01.016     Document Type: Article

References (12)

1. T. Matsumoto, M. Ito, Y. Hayashi, T. Hirota, Y. Tanigawara, T. Sone, M. Fukunaga, M. Shiraki, and T. Nakamura A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - a randomized, active comparator, double-blind study Bone 49 4 2011 605 612
2. D.M. Mitchell, S. Regan, M.R. Cooley, K.B. Lauter, M.C. Vrla, C.B. Becker, S.A. Burnett-Bowie, and M. Mannstadt Long-term follow-up of patients with hypoparathyroidism J. Clin. Endocrinol. Metab. 97 12 2012 4507 4514
3. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group Ann. Intern. Med. 130 6 1999 461 470
4. Y. Ono Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment J. Steroid. Biochem. Mol. Biol. 139 2014 88 97
5. S. Hatakeyama, S. Nagashima, N. Imai, K. Takahashi, J. Ishihara, A. Sugita, T. Nihei, H. Saito, F. Takahashi, and N. Kubodera Synthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71) J. Steroid. Biochem. Mol. Biol. 103 3-5 2007 222 226
6. M. Abe, N. Tsuji, F. Takahashi, and Y. Tanigawara Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative Jpn. Pharmacol. Ther. 39 2011 261 274
7. T. Furuichi, S. Kawata, Y. Asoh, K. Kumaki, and Y. Ohyama Differential time course of induction of 1α,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1α,25-dihydroxyvitamin D3 and its analogs Life Sci. 62 5 1998 453 459
8. C.S. Ritter, and A.J. Brown Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism J. Cell. Biochem. 112 5 2011 1348 1352
9. T. Matsumoto, T. Miki, H. Hagino, T. Sugimoto, S. Okamoto, T. Hirota, Y. Tanigawara, Y. Hayashi, M. Fukunaga, M. Shiraki, and T. Nakamura A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial J. Clin. Endocrinol. Metab. 90 9 2005 5031 5036
10. R.B. Payne, A.J. Little, R.B. Williams, and J.R. Milner Interpretation of serum calcium in patients with abnormal serum proteins BMJ 4 1973 643 646
11. Y. Uchiyama, Y. Higuchi, S. Takeda, T. Masaki, A. Shira-ishi, K. Sato, N. Kubodera, K. Ikeda, and E. Ogata ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis Bone 30 4 2002 582 588
12. T. Matsumoto, T. Takano, S. Yamakido, F. Takahashi, and N. Tsuji Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism J. Steroid. Biochem. Mol. Biol. 121 1-2 2010 261 264